-
Mashup Score: 0Brief Report: Longitudinal tracking of ALK rearranged non-small cell lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA - 11 hour(s) ago
While the administration of tyrosine-kinase inhibitors (TKIs) in ALK rearranged non-small cell lung cancer (NSCLC) has revolutionized precision medicine, detection of gene rearrangements from liquid biopsies remains challenging. RNA-based detection has demonstrated promising sensitivity for rearrangement detection and thus we hypothesize that a liquid biopsy assay analyzing circulating-tumor RNA (ctRNA) in addition to circulating-tumor DNA (ctDNA) will improve detection. Furthermore, we hypothesize that detection of gene fusions at baseline will correlate with clinical outcome.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 26Molecular Marker Testing in Curable Non–Small Cell Lung Cancer - 2 year(s) ago
This Viewpoint describes the use of broad molecular marker testing in patients with early-stage non–small cell lung cancer
Source: jamanetwork.comCategories: Latest Headlines, Oncologists2Tweet-
RT @CharuAggarwalMD: Molecular Testing in Early Stage NSCLC @JAMAOnc https://t.co/nRW5aqlolX @JackWestMD and I discuss that it is most app…
-
-
Mashup Score: 0Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant - PubMed - 2 year(s) ago
Poly (ADP-ribose) polymerase (PARP) inhibitors have been approved in malignancies associated with germline BRCA1 or BRCA2 pathogenic variants, such as breast, ovarian, prostate, and pancreatic cancer. In malignancies not associated with germline BRCA1 or BRCA2 pathogenic …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Successful olaparib use in metastatic NSCLC with a somatic BRCA2 pathogenic variant - congratulations to @JB_Chiang @danieltanmd @jongeow https://t.co/sejgdhnoHH https://t.co/eAYLWNO5Fa
-
-
Mashup Score: 23Closing the Gap in Cancer Genomic Testing | NEJM - 2 year(s) ago
Perspective from The New England Journal of Medicine — Closing the Gap in Cancer Genomic Testing
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @rschilsky: Genomic testing a key part of cancer care. https://t.co/B8EEsf1Ub2
-
-
Mashup Score: 9ISLB || International Society of Liquid Biopsy - 2 year(s) ago
ISLB is the first international professional organization for the improvement of liquid biopsies in clinical routine practice
Source: ISLBCategories: Latest Headlines, Oncologists2Tweet-
RT @ChristianRolfo: Starting today our #ISLB22 in Miami! You can follow virtually and on demand! https://t.co/mI4vVohxF3 . A comprehensive…
-
-
Mashup Score: 0Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non–Small Cell Lung Cancer - 3 year(s) ago
This cross-sectional epidemiological analysis calculated the most recent epidemiological estimates of incidence, prevalence, and survival in patients with non–small cell lung cancer, and describes initial treatment overall and by stage in the US.
Source: jamanetwork.comCategories: Latest Headlines, Oncologists2Tweet-
Good news - NSCLC incidence downtrend (2010-2017) in JAMA Oncology. Better detection with radiologic screening scans works. Also smoking downtrends help - CDC reports adult smoking % in 2005 fell from 21% to 14% in 2019. https://t.co/Moy7T1Bd6W
-
-
Mashup Score: 0Effective gene expression prediction from sequence by integrating long-range interactions - Nature Methods - 3 year(s) ago
By using a new deep learning architecture, Enformer leverages long-range information to improve prediction of gene expression on the basis of DNA sequence.
Source: Nature MethodsCategories: Latest Headlines, Oncologists2Tweet-
First application of transformers to DNA sequence analysis. Transformer ML models revolutionized automated language translation (think Google Translate). DNA sequence = another new language! https://t.co/E9n41hzkas
-
-
Mashup Score: 6BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD - 4 year(s) ago
Deal strengthens BioNTech’s cell therapy pipeline by accelerating individualized solid tumor Neoantigen TCR cell therapy research and development program…
Source: GlobeNewswire News RoomCategories: Latest Headlines, Oncologists2Tweet-
RT @matthewherper: $BNTX buys Kites TCR platform + associated manufacturing. (correcting previous tweet.) https://t.co/eA6xiEea17
-
-
Mashup Score: 12NRG1 fusions: Biology to therapy - 4 year(s) ago
In the current era of precision medicine, the proper management of advanced non-small cell lung cancer (NSCLC) is completely dependent on the presence or absence of actionable driver alterations. [1] These drivers are early transforming events that define the malignancy; they are retained and are not lost over time. They dictate the biology of the cancer and its clinical behavior. Most…
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @StephenVLiu: Brief review on #NRG1 fusions in lung cancer online now @LungCaJournal #LCSM https://t.co/1oHi7Wx8u4
-
-
Mashup Score: 2
Article InfoPublication HistoryAccepted: June 21, 2021Received in revised form: June 3, 2021Received: February 28, 2021Publication stageIn Press Journal Pre-ProofFootnotesCRediT StatementConceptualization: Christian Rolfo, Philip Mack, Giorgio V. Scagliotti, David GandaraWriting – Original Draft: Christian Rolfo, Giorgio V….
Source: Journal of Thoracic OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @isliquidbiopsy: https://t.co/HK2oOCd0YH
-
Amazing work from @HeekeSimon @YYElamin and MD Anderson team! ctDNA + ctRNA >> ctDNA only https://t.co/KhF512P76S